Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

Autor: Kun Wang, Zi-Hao Xing, Qi-Wei Jiang, Yang Yang, Jia-Rong Huang, Meng-Ling Yuan, Meng-Ning Wei, Yao Li, Sheng-Te Wang, Kun Liu, Zhi Shi
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Frontiers in Oncology, Vol 9 (2019)
Druh dokumentu: article
ISSN: 2234-943X
DOI: 10.3389/fonc.2019.00080
Popis: Urokinase plasminogen activator receptor (uPAR), a member of the lymphocyte antigen 6 protein superfamily, is overexpressed in different types of cancers and plays an important role in tumorigenesis and development. In this study, we successfully targeted uPAR by CRISPR/Cas9 system in two human cancer cell lines with two individual sgRNAs. Knockout of uPAR inhibited cell proliferation, migration and invasion. Furthermore, knockout of uPAR decreases resistance to 5-FU, cisplatin, docetaxel, and doxorubicin in these cells. Although there are several limitations in the application of CRISPR/Cas9 system for cancer patients, our study offers valuable evidences for the role of uPAR in cancer malignancy and drug resistance.
Databáze: Directory of Open Access Journals